United States · Platforms & data · Morningstar

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Published by Morningstar · United States 9 h ago

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the…

Read the full article on Morningstar Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

MarketBeat

Vor Biopharma Inc. (VOR) - What Are Investment Firms Thinking About This Stock?

Seeking Alpha

Zai Lab announces $250M private placement

MarketWatch

We have a $300,000 mortgage with a 2.75% interest rate. I want to pay it off. My husband says I’m crazy. Who’s right?

The Motley Fool

This Top Investment Strategist Thinks a Bitcoin Supercycle Is Coming Soon. Here's Why He's Wrong.

Investing.com

OpenAI and Poland’s NASK collaborate on AI safety research

Yahoo Finance